L Murillo-Sanjuán1, J Balmaña2, A de Pablo García-Cuenca3, J Lorente Guerrero4, M L Uria Oficialdegui1, E Carrasco2, C Diaz-de-Heredia5. 1. Department of Pediatric Oncology and Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 2. Department of Medical Oncology and Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain. 3. Department of Oral and Maxillofacial Surgery, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 4. Department of Otorhinolaryngology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 5. Department of Pediatric Oncology and Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. crdiaz@vhebron.net.
Abstract
INTRODUCTION: Hematopoietic stem cell transplantation (HSCT) is a curative option for patients with Fanconi anemia (FA) and hematological manifestations but it does not prevent solid tumors, especially squamous cell carcinomas (SCC). METHODS: Retrospective study in 22 FA patients who had received HSCT and had been followed up beyond 2 years after HSCT. RESULTS: The median follow-up was 15 years. Six patients developed head-and-neck SCC after transplantation. The cumulative incidence of SCC at 15 and 30 years from the HSCT was 14.2% and 71.2%, respectively. One patient was diagnosed in stage IV and the rest, who were being followed up in cancer screening programs, in stage I. Treatment of SCC consisted of surgery in all patients; radiotherapy and chemotherapy were used in two patients and were poorly tolerated. CONCLUSION: FA patients have high risk of head-and-neck SCC. Multi-disciplinary programs for early cancer detection are of special relevance in these patients.
INTRODUCTION: Hematopoietic stem cell transplantation (HSCT) is a curative option for patients with Fanconi anemia (FA) and hematological manifestations but it does not prevent solid tumors, especially squamous cell carcinomas (SCC). METHODS: Retrospective study in 22 FA patients who had received HSCT and had been followed up beyond 2 years after HSCT. RESULTS: The median follow-up was 15 years. Six patients developed head-and-neck SCC after transplantation. The cumulative incidence of SCC at 15 and 30 years from the HSCT was 14.2% and 71.2%, respectively. One patient was diagnosed in stage IV and the rest, who were being followed up in cancer screening programs, in stage I. Treatment of SCC consisted of surgery in all patients; radiotherapy and chemotherapy were used in two patients and were poorly tolerated. CONCLUSION: FA patients have high risk of head-and-neck SCC. Multi-disciplinary programs for early cancer detection are of special relevance in these patients.
Authors: David I Kutler; Krupa R Patel; Arleen D Auerbach; Jennifer Kennedy; Francis P Lach; Erica Sanborn; Marc A Cohen; William I Kuhel; Agata Smogorzewska Journal: Laryngoscope Date: 2015-10-20 Impact factor: 3.325
Authors: Thomas H Beckham; Jonathan Leeman; Chiaojung Jillian Tsai; Nadeem Riaz; Eric Sherman; Bhuvanesh Singh; Nancy Lee; Sean McBride; Daniel S Higginson Journal: Head Neck Date: 2019-01-11 Impact factor: 3.147
Authors: Eunike Velleuer; Ralf Dietrich; Natalia Pomjanski; Isabela Karoline de Santana Almeida Araujo; Bruno Eduardo Silva de Araujo; Isis Sroka; Stefan Biesterfeld; Alfred Böcking; Martin Schramm Journal: Cancer Cytopathol Date: 2020-02-05 Impact factor: 5.284
Authors: Winnifred M Wong; Upendra Parvathaneni; Patrick D Jewell; Renato G Martins; Neal D Futran; George E Laramore; Jay J Liao Journal: Head Neck Date: 2012-09-10 Impact factor: 3.147
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245